Scientific Program

ATTD is the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes, assemble with the aim to be share knowledge and develop collaborations.

Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.

List of Confirmed Titles and Speakers*

Ananta Addala USA The role of perceived discrimination in diabetes disparities: Experience of underrepresented individuals
Peter Adolfsson Sweden How are data being integrated into EHRs
Usage of smart pens in pediatric population
Halis Akturk USA The role of CGM in early detection of Immune checkpoint inhibitor (Cancer immunotherapy) induced type 1 diabetes
Stephanie Amiel UK CLEAR and HARPdoc – new learning from studies in impaired hypoglycaemia awareness
Robert Andrews UK CGM in non-diabetic hypoglycaemia (insulinoma, post-bariatric / reactive)
Lia Bally UK Beyond glycemia: addressing overweight and obesity in type 1 diabetes
Katharine Barnard-Kelly UK Impact of screening and understanding the risk
Improving glycemic control and reducing diabetes distress: a 2-way street
Roy Beck USA Afrezza use in pediatrics – INHALE 1 study
Richard Bergenstal UK Adapting CGM Reports for the use in Real Life
DEBATE: HbA1c and not CGM should be the gold standard to evaluate glucose control – CON
Riccardo Bonfanti Italy The role of technology in monitoring and managing presymptomatic (stage 1&2) type 1 diabetes in children following screening
Emanuele Bosi Italy Monitoring children with early type 1 diabetes: the Italian experience
Anne-Sophie Brazeau Canada Food choices matter: The impact of dietary patterns on glucose control when using automated insulin delivery
Marc Breton USA Fully automated closed loop based on artificial intelligence
Adrian Brown UK Essential nutrition support for GLP-1/GIP therapy success
Giacomo Cappon Italy Combining digital twins and LLMs for advanced personalized insulin therapy in type1 diabetes
Per-Ola Carlsson Sweden Hypoimmune pancreatic islet transplantation in type 1 diabetes
Eda Cengiz USA Shifting the paradigm: Innovations in gender-specific diabetes technology
Pratik Choudhary UK CGM use in clinical trials
Iain Cranston UK Data standards and data ownership for device interoperability: The NHSE / PRSB experience & debate
Tali Cukierman-Yaffe Israel Practical guidance on use of AID in a heterogenous population of older adults with diabetes
Deniz Dalton USA Helmsley funding areas and Type 1 Diabetes and eXercise Initiative (T1-DEXI)
Hans De Vries the Nathrlands CGM in type 2 diabetes
Katy Digovich USA Minutia: Leveraging our nanoparticle platform for safety and success with our minimally invasive sc-islet transplant
Klemen Dovc Slovenia Is VO2max important for exercise planning
Robert Eckel USA Differences in pathology from type 2 diabetes
Dominic Ehrmann Germany HCPs and Patients’ view on Smart Pens: Results of the dt-report 2025
Anas El Fathi USA A week of automated insulin delivery used to titrate basal insulin in type 2 diabetes
Chiara Fabris USA Digital twins to improve glycemic management in females with type 1 diabetes
CGM metrics predicted microvascular diabetes complications
Andrea Facchinetti Italy Advanced CGM/AI-based algorithms for diabetes
Gregory Forlenza USA Is ultra-fast acting insulin improving AID – the evidence is mixed, but there is a catch
Jason Gaglia USA Dendritic cells for treatment of type 1 diabetes
Robin L. Gal USA Moving forward with exercise: Insulin and education strategies for glycemic management
Gerlandine Gallen UK Beyond the Device: The Importance of Leadership and Mentorship for Diabetes Educators
Satish Garg USA Ways to overcome challenges in GLP use in type 1 diabetes
CGM frequency use in type 2 diabetes
Nicola Guess UK CGM as a guide to lifestyle and weight management
Amit Gupta India Benchmarking better: Using technology to align practice with evolving diabetes care guidelines
Ahmad Haidar Canada Concurrent use of AID with SGLT-2
Michael Haller USA Screening programs for type 1 diabetes in the US: From research to standard of care
Lutz Heinemann Germany Non-invasive glucose monitoring
Irl Hirsch USA “I’ve run out of real estate”- why some patients struggle with insulin pump therapy
Understanding the etiology and best treatment strategies for obesity in type 1 diabetes
Korey Hood USA Experience of being anti-body positive and choices available
William Horton USA CGM-based prediction of cardiovascular outcomes in diabetes
Roman Hovorka UK Comparing automated insulin delivery systems (AIDs): The good, the bad and the ugly
Sufyan Hussain UK Lessons from open-source systems
Fasting during the night with hybrid Closed-loop
Concetta Irace Italy Connected pens in type 2 diabetes
Johan` Jendle Sweden The need for interoperability
Next generation of smart pens
Anna Kahkoska USA Challenges of growing older with type 1 diabetes as a female
Partha Kar UK Challenging industry or widening gaps in access to technology
Boris Kovatchev USA Could CGM replace antibodies screening?
How AI can help the human-machine co-regulation of diabetes
The continuum between hybrid and fully-automated closed-loop
Yogish C. Kudva USA Current evidence for use of AID systems in older adults with diabetes
Lori Laffel USA Executive function and use of diabetes technologies
Rayhan Lal USA Closed-loop systems: Future challenges and considerations
Janni Larsson Denmark Diabetic retinopathy in relation to pregnancy
Alon Liberman Israel The role of psychological interventions in promoting sustainable weight loss
Yu Kuei (Alex) Lin USA Hypoglycemia risk in type 2 diabetes on CGM
David Maahs USA Bridging the gap between population screening and immunotherapy
Targeting lower glucose levels in children with type 1 diabetes
Julia Mader Austria Using apps to support management of type 2 diabetes
Clinical Evidence for Smart Pens
Thomas Martens USA Technology implementation in primary care: what is the best model?
Chantal Mathieu Belgium Experience of EDENTIFI clinical study
C-peptide: A marker for functional beta cell mass?
Shweta Mital Canada Cost Effectiveness of Screening and Immune Interventions in type 1 diabetes
Viswanathan Mohan India Subtypes of prediabetes
Dale Morrison Australia Use of whey protein to reduce risk of hypoglycemia during exercise for people with type 1 diabetes
Medha Munshi USA Challenges & barriers to use of AID systems in older adult patient and health care provider perspective
Helen Murphy UK Pregnancy outcomes in early-onset type 2 diabetes
Revital Nimri Israel Twenty-four-hour fasting with hybrid closed-loop
Kirsten Nørgaard Denmark What are the physiological differences during exercise in type 1 diabetes compared to healthy individuals?
Tal Oron Israel Together with Moshe Phillip – Israeli Experience: ADIR – General population and families screening
Naushira Pandya USA Challenges and opportunities of using technology in rehabilitation, nursing homes and assisted living settings
Rakesh Parikh India Generative AI as patient education partner
Francisco J. Pasquel USA Real-life data on GLP use in type 1 diabetes
Moshe Phillip Israel Together withTal Oron – Israeli Experience: ADIR – General population and families screening
Tamar Propper-Lewinsohn Israel Technology and disordered eating behavior in type 1 diabetes management
Wu Qian China Randomized Trial of an Adaptive AI-Based VR Sports System for Adolescents at Risk of Type 2 Diabetes
Ivana Rabbone Italy Long-term impact of early advanced technology adoption (CGM/AID) on hypoglycemia awareness and fear in children and families
Yves Reznik France Automated insulin delivery in type 2 diabetes
Michael Riddell Canada Lactate metabolism and why a continuous lactate monitor might be of value
Physical activity for Cardiometabolic risk reduction in type 1 diabetes
Teresa Rodriguez-Calvo Germany Role of viruses in pathogenesis of type 1 diabetes
Martina Rothenbühler Switzerland Interplay between the menstrual cycle and type 1 diabetes management
Holger Russ USA Stem cell derived beta cells for cell therapy: Progress, hurdles and future directions
Banshi Saboo India Showcasing area-side improvement in type 1 diabetes across India
Andrea Scaramuzza Italy Frequency of diabetic ketoacidosis following pilot screening for type 1 diabetes in the general Italian population
Desmond Schatz USA Is it time to re-evaluate our recommendations for screening the general population for risk for type 1 diabetes?
Oliver Schnell Germany Targets and best therapies for blood pressure and cholesterol
Eleanor Scott UK Expanding CGM use in GDM pregnancy
Jane Jeffrie Seley USA “To wear or not to wear” integrating wearable technology into Adult Diabetes Care
Elizabeth Selvin USA DEBATE: HbA1c and not CGM should be the gold standard to evaluate glucose control – PRO
Viral Shah USA ADJUST T1D study – design and glycemic outcome
CGM for prediabetes
Devorah Shapiro Israel How to help our children with diabetes choose the best diabetes technology for them? A tailored and personalized method
Jennifer Sherr USA Optimizing AID systems: Strategies for enhanced glycemic control
Smadar Shilo Israel CGM in individuals without diabetes
Alpana Shukla USA Benefits of meal sequencing in a variety of populations: T1D, T2D and prediabetes
Jay Skyler USA Challenges in the treatment of type 1 diabetes
Janet Snell-Bergeon USA ADJUST T1D study – Cardiovascular outcomes
MERIT:  Impact of menstruation on glycemic response and exercise in females with type 1 diabetes
Tim Street UK AI for Carb Counting and Insulin Dosing: How not to do it
Jannet Svensson Denmark Adhesives from pumps and sensors: how to best address allergy and inflammation
Maria Vasiloglou Switzerland Evidence-based apps that improve nutrition and diabetes outcome
Josep Vehi Spain Glycemic control with AI & ML: Lessons learned and next steps
Piotr Witkowski USA Optimizing Immunomodulation to Improve Outcomes of Beta Cell Replacement Therapy in Patients with T1DM
Yariv Yogev Israel What is new in pregnancy complicated by diabetes
Dessi Zaharieva USA Type 1 diabetes and exercise education & information resources, upcoming innovative solutions, and INSPIRE-T1D
Exercise and TYPE 1 DIABETES: Clinical trials versus real-world evidence – which tells the full story?

*List of Confirmed Titles and Speakers as of 16 September, 2025